MedTrace Logo

Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients

NCT02965326 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2024-03-12

No results posted yet for this study

Summary

The purpose of this study is to determine which biological marker, or association of biological markers, best predict clinical response of cystic fibrosis patients to CFTR modulators.

Conditions

Interventions

PROCEDURE

Nasal swab; rectal biopsy.

Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.

Sponsors & Collaborators

  • Association Mucoviscidose-ABCF2

    collaborator OTHER

  • Vaincre la Mucoviscidose

    collaborator OTHER

  • Hôpital Necker-Enfants Malades

    lead OTHER

Principal Investigators

  • Aleksander Edelman, phD · APHP

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2026-03-31
Completion
2026-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02965326 on ClinicalTrials.gov